Author name: Kristen Hartman

Aversive stimulus attenuates impairment of acquisition in a delayed match to position T-maze task caused by a selective lesion of septo-hippocampal cholinergic projections.

Fitz NF, Gibbs RB, Johnson DA (2006) Aversive stimulus attenuates impairment of acquisition in a delayed match to position T-maze task caused by a selective lesion of septo-hippocampal cholinergic projections. Brain Res Bull 69(6):660-665. doi: 10.1016/j.brainresbull.2006.03.011 Summary: It is known that infusion of 192-IgG-SAP (Cat. #IT-01) into the medial septum of rats impairs acquisition of […]

Aversive stimulus attenuates impairment of acquisition in a delayed match to position T-maze task caused by a selective lesion of septo-hippocampal cholinergic projections. Read More »

Differential responsiveness of dopamine-beta-hydroxylase gene expression to glucoprivation in different catecholamine cell groups.

Li AJ, Wang Q, Ritter S (2006) Differential responsiveness of dopamine-beta-hydroxylase gene expression to glucoprivation in different catecholamine cell groups. Endocrinology 147(7):3428-3434. doi: 10.1210/en.2006-0235 Summary: This work examines how subpopulations of hindbrain catecholaminergic neurons participate in systemic glucoregulation. Rats were treated with bilateral 42 ng infusions of anti-DBH-SAP (Cat. #IT-03) into the paraventricular nucleus of

Differential responsiveness of dopamine-beta-hydroxylase gene expression to glucoprivation in different catecholamine cell groups. Read More »

Targeting Tools: Fluorescent Conjugates

News Tools /

Antibodies conjugated to fluorescent dyes are vibrant and vital tools at a scientist’s disposal. ATS currently has six fluorescent conjugates in our catalog: Cy3-labeled 192-IgG (Cat. #AB-N43FL3), FITC-labeled Anti-Saporin (Cat. #AB-15APFL), Alexa 488-labeled 192-IgG (Cat. #AB-N43FLA), FITC-labeled Goat anti-rabbit IgG (Cat. #FL-04), Cy3- labeled anti-NGFr (Cat. #AB-N01APFL3), and Cy5-labeled anti- NGFr (Cat. #AB-N01APFL5). ATS also

Targeting Tools: Fluorescent Conjugates Read More »

Retrograde Transport

Q: I spoke with someone from your technical service over the phone and got the impression that your product dermorphin-SAP (Cat. #IT-12) is not a retrograde and will only affect the terminals or the cells that express mu opioid receptors in the injection site in the brain. I have three questions: 1) Do you have

Retrograde Transport Read More »

Effect of nucleus basalis magnocellularis cholinergic lesions on fear-like and anxiety-like behavior.

Knox D, Berntson GG (2006) Effect of nucleus basalis magnocellularis cholinergic lesions on fear-like and anxiety-like behavior. Behav Neurosci 120(2):307-312. doi: 10.1037/0735-7044.120.2.307 Summary: Neurons in the nucleus basalis magnocellularis and substantia innominata (NBM/SI) may play a role in mediating some aspects of aversive states. The authors used 0.1 µg injections of 192-IgG-SAP (Cat. #IT-01) into

Effect of nucleus basalis magnocellularis cholinergic lesions on fear-like and anxiety-like behavior. Read More »

Chronic Pain Drug – Update on SP-SAP Development

SP SAP Drug Development /

ATS continues to make progress toward human clinical trials with SP-SAP. Thanks to the financial support of the National Institutes of Health, National Institute of Mental Health, preclinical studies have been completed, protocols for drug production have been written and the first of two toxicology studies is done. This first study is a GLP toxicology

Chronic Pain Drug – Update on SP-SAP Development Read More »

Cover Article: Targeted Toxins in Pain

News Article /

Summary of contribution to “Recontres en toxinologie, 2005”by Ronald G. Wiley, Neurology Service (127) – VA TVHS, 1310 24th Avenue, South, Nashville, TN 37212 The use of targeted toxins in neuroscience research has evolved over the past twenty-plus years from original suicide transport lesions using ricin to highly selective neuron type-specific lesions made with immunotoxins,

Cover Article: Targeted Toxins in Pain Read More »

The growth and tumor suppressor NORE1A is a cytoskeletal protein that suppresses growth by inhibition of the ERK pathway

Moshnikova A, Frye J, Shay JW, Minna JD, Khokhlatchev AV (2006) The growth and tumor suppressor NORE1A is a cytoskeletal protein that suppresses growth by inhibition of the ERK pathway. J Biol Chem 281(12):8143-8152. doi: 10.1074/jbc.M511837200 PMID: 16421102 Related Products: Antibody to NORE1A (10F10-C6-C6) (Cat. #AB-V56)

The growth and tumor suppressor NORE1A is a cytoskeletal protein that suppresses growth by inhibition of the ERK pathway Read More »

Purkinje cell loss by OX7-saporin impairs acquisition and extinction of eyeblink conditioning.

Nolan BC, Freeman JH (2006) Purkinje cell loss by OX7-saporin impairs acquisition and extinction of eyeblink conditioning. Learn Mem 13(3):359-365. doi: 10.1101/lm.168506 Summary: Adaptive adjustments to movements depend on cerebellar learning. This work examines the effect of a global depletion of Purkinje cells in the cerebellar cortex on delay eyeblink conditioning in rats. 15 µg

Purkinje cell loss by OX7-saporin impairs acquisition and extinction of eyeblink conditioning. Read More »

Search
Shopping Cart
Scroll to Top